Regen BioPharma, Inc. RGBP OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score

28/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Regen BioPharma, Inc. (RGBP) .

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 26/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

28/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

PAST

50/100

→ Income

✗

HEALTH

0/100

Debt-to-Equity & liquidity

→ Health

MOAT

50/100

→ Income

✗

GROWTH

30/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — RGBP

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.06

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-0.05

Book Value / Share$0.00

Revenue / Share$0.01

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-40.05	$100K	$-3.41M	-3414%
2017	$-61.93	$110K	$-5.84M	-5308.2%
2018	$-46.50	$100K	$-4.72M	-4715%
2019	$-1.95	$110K	$-2.62M	-2384.5%
2020	$1.90	$110K	$2.73M	2483.6%
2021	$-1.69	$171.19K	$-6.77M	-3951.7%
2022	$0.36	$235.52K	$2.23M	945.6%
2023	$0.14	$236.56K	$1.02M	432.9%
2024	$-0.08	$236.56K	$-668K	-282.4%
2025	$-0.05	$236.56K	$-1.27M	-538.8%